Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.

, , , , ,,
Trends in Molecular Medicine
Department of Medical Oncology

Gilham, D., Debets, R., Pule, M., Hawkins, R., & Abken, H. (2012). CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends in Molecular Medicine (Vol. 18, pp. 377–384). doi:10.1016/j.molmed.2012.04.009